Benefits can include: Lower blood pressure Lower total cholesterol Better liver health for those with metabolic dysfunctionassociated steatotic liver disease (MASLD) Lower blood sugar and reduced diabetes risk Lower risk of kidney disease Tirzepatide and orforglipron are newer drugs that dont yet have results from long-term cardiovascular health trials
Among 169,649 patients with MASLD, GLP-1 receptor agonist initiation was linked to significantly lower probability of incident cirrhosis [adjusted hazard ratio (aHR): 0.86, 95%CI: 0.80-0.93], hepatic decompensation (aHR: 0.77, 95%CI: 0.65-0.90), and hepatocellular carcinoma (HCC) (aHR: 0.79, 95%CI: 0.68-0.92) over a median follow-up of 3.5 years compared to non-users
There is no universal retatrutide dosage calculator that fits everyone, so your provider will carefully determine your retatrutide starting dose and titration schedule
Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia
Your provider will discuss expectations, monitoring, and follow-up during consultation
The hormonal and neurological drivers of appetite return to baseline